Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact Mark on +44 1494 818 049 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Mark Denton
Managing Director
+44 1494 818 049

I want to thank Zenopa for their time and efforts in helping me during my job search, you have given me the extra confidence I need to keep me pro-active in my search.
Mohammed, 2011

Actelion announces results of arbitration meeting with Asahi Kasei Pharma Corporation

7 January 2010 00:00 in Pharmaceutical Company Financials

Actelion has issued a report on the results of an arbitration proceeding session between CoTherix - one of its subsidiaries - and Asahi Kasei Pharma Corporation.

The pharmaceutical firm explained that the meeting related to a licence agreement to develop Asahi Kasei's rho kinase inhibitor fasudil.

It stated that the Asahi Kasei and CoTherix entered into an initial agreement relating to the therapy in June 2006 and this was followed by the acquisition of 100 per cent of all issued and outstanding shares of the latter firm by Actelion in January 2007.

CoTherix has since been a wholly-owned, separate subsidiary of Actelion and advised Asahi Kasei that it would not continue the development of fasudil in January 2007, returning the product to the Japanese firm - which operates around the world, including the UK.

"The arbitration panel has now reached a decision that CoTherix should pay Asahi Kasei approximately $91 million (56.9 million pounds) plus interest," Actelion concluded.

Other news stories from 07/01/2010

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2015 Zenopa Ltd